These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36509537)

  • 1. [Comparative study of hypersensitive quantitative fecal immunochemical test and qualitative fecal occult blood test for colorectal cancer and advanced adenoma].
    Zhou RC; Wang PZ; Ma MJ; Meng FY; Li YY; Zhang Y; Yang XY; Li YQ; Zuo XL
    Zhonghua Yi Xue Za Zhi; 2022 Dec; 102(46):3667-3672. PubMed ID: 36509537
    [No Abstract]   [Full Text] [Related]  

  • 2. Quantitative immunochemical fecal occult blood test for neoplasia in colon cancer screening.
    Yuan SY; Wu W; Fu J; Lang YX; Li JC; Guo Y; Wang YN; Qian JM; Li JN
    J Dig Dis; 2019 Feb; 20(2):78-82. PubMed ID: 30714346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection.
    Hundt S; Haug U; Brenner H
    Ann Intern Med; 2009 Feb; 150(3):162-9. PubMed ID: 19189905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Preliminary application of the Asia-Pacific colorectal screening score combined with the quantitative fecal occult blood in colorectal neoplasia screening].
    Kang Q; Li N; Wang RF; Yang L; Jin P; Sheng JQ
    Zhonghua Yi Xue Za Zhi; 2021 Dec; 101(46):3825-3828. PubMed ID: 34895425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison between application of fecal occult blood quantitive testing instrument and colloidal gold strip method in colorectal cancer screening].
    Huang YQ; Zhang MW; Shen YZ; Ma HQ; Cai SR; Zhang SZ; Zheng S
    Zhonghua Yu Fang Yi Xue Za Zhi; 2013 Aug; 47(8):747-51. PubMed ID: 24246083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the performance of guaiac-based and two immunochemical fecal occult blood tests for identifying advanced colorectal neoplasia in Taiwan.
    Ou CH; Kuo FC; Hsu WH; Lu CY; Yu FJ; Kuo CH; Wang JY; Wu MT; Shiea J; Wu DC; Hu HM
    J Dig Dis; 2013 Sep; 14(9):474-83. PubMed ID: 23701988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests.
    Haug U; Hundt S; Brenner H
    Am J Gastroenterol; 2010 Mar; 105(3):682-90. PubMed ID: 19953091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A quantitative immunochemical fecal occult blood test for colorectal neoplasia.
    Levi Z; Rozen P; Hazazi R; Vilkin A; Waked A; Maoz E; Birkenfeld S; Leshno M; Niv Y
    Ann Intern Med; 2007 Feb; 146(4):244-55. PubMed ID: 17310048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening.
    Park DI; Ryu S; Kim YH; Lee SH; Lee CK; Eun CS; Han DS
    Am J Gastroenterol; 2010 Sep; 105(9):2017-25. PubMed ID: 20502450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diagnostic performance of quantitative fecal immunochemical test in detection of advanced colorectal neoplasia].
    Lu M; Chen HD; Liu CC; Zhang YH; Wei LP; Lyu ZY; Ren JS; Shi JF; Zou SM; Li N; Dai M
    Zhonghua Liu Xing Bing Xue Za Zhi; 2020 Dec; 41(12):2104-2111. PubMed ID: 33378824
    [No Abstract]   [Full Text] [Related]  

  • 11. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
    van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; van Krieken HH; Verbeek AL; Jansen JB; Dekker E
    Gastroenterology; 2008 Jul; 135(1):82-90. PubMed ID: 18482589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of a Single Aspirin Dose Prior to Fecal Immunochemical Testing on Test Sensitivity for Detecting Advanced Colorectal Neoplasms: A Randomized Clinical Trial.
    Brenner H; Calderazzo S; Seufferlein T; Ludwig L; Dikopoulos N; Mangold J; Böck W; Stolz T; Eisenbach T; Block T; Kopp-Schneider A; Czock D; Tikk K
    JAMA; 2019 May; 321(17):1686-1692. PubMed ID: 31063574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The clinical value of multi-target stool fecal immunochemical test-DNA in early screening and diagnosis for colorectal cancer].
    Li YL; Guan X; Dou LZ; Liu Y; Huang HY; Huang SK; Yang ZX; Wei BJ; Wu Y; Chen ZH; Wang GQ; Wang X; Cui W
    Zhonghua Yi Xue Za Zhi; 2022 Sep; 102(33):2607-2613. PubMed ID: 36058686
    [No Abstract]   [Full Text] [Related]  

  • 14. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of new non-invasive tests for colorectal cancer screening: the relevance of information on adenoma detection.
    Haug U; Knudsen AB; Lansdorp-Vogelaar I; Kuntz KM
    Int J Cancer; 2015 Jun; 136(12):2864-74. PubMed ID: 25403937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of a New-generation Fecal Immunochemical Test (FIT) With Guaiac Fecal Occult Blood Test (gFOBT) in Detecting Colorectal Neoplasia Among Colonoscopy-referral Patients.
    Guimarães DP; Fregnani JH; Reis RM; Taveira LN; Scapulatempo-Neto C; Matsushita M; Silva SRM; Oliveira CZ; Longatto-Filho A; Eklund C; Paloheimo L; Mauad E; Suovaniemi O; Syrjänen K
    Anticancer Res; 2019 Jan; 39(1):261-269. PubMed ID: 30591467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
    Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
    J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of colorectal adenomas by a quantitative immunochemical faecal occult blood screening test depends on adenoma characteristics, development threshold used and number of tests performed.
    Rozen P; Levi Z; Hazazi R; Waked A; Vilkin A; Maoz E; Birkenfeld S; Leshno M; Niv Y
    Aliment Pharmacol Ther; 2009 Apr; 29(8):906-17. PubMed ID: 19183147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colorectal cancer screening with fecal immunochemical testing: a community-based, cross-sectional study in average-risk individuals in Nigeria.
    Alatise OI; Dare AJ; Akinyemi PA; Abdulkareem FB; Olatoke SA; Knapp GC; Kingham TP;
    Lancet Glob Health; 2022 Jul; 10(7):e1012-e1022. PubMed ID: 35714629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy comparison among high risk factors questionnaire and Asia-Pacific colorectal screening score and their combinations with fecal immunochemical test in screening advanced colorectal tumor].
    Zhu N; Huang YQ; Song YM; Zhang SZ; Zheng S; Yuan Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Jul; 25(7):612-620. PubMed ID: 35844124
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.